[제약&바이오] JW New Testament
JW Shinyak is a pharmaceutical company that has established itself as a specialized maker in the clinic market. It produces and supplies excellent medicines that improve the quality of people’s lives and is leading the domestic clinic market targeting specialized hospitals and clinics such as dermatology, pediatrics, otolaryngology, and urology.
JW Shinyak has recently been attracting attention for its aggressive business expansion, including expanding its hair loss treatment portfolio and entering the hair care cosmetics market. This year, JW Shinyak aims to achieve sales of 30 billion won for its hair loss-related product line, and aims to sell 5 billion won for its newly launched hair care cosmetics.
Leading the hair loss market with products that can be prescribed depending on the cause of hair loss
JW Shinyak has a diverse portfolio of hair loss treatments that can be prescribed depending on the cause of hair loss, such as genetics, childbirth, and seborrheic dermatitis. In particular, it is solidifying its position in the hair loss treatment market by possessing a variety of oral hair loss treatment products such as ‘Monad Tablets’ with finasteride as the main ingredient and ‘Neodat Tablets’ with dutasteride as the main ingredient. JW Shinyak’s Monad tablets have been ranked first in sales of generics of the same class for several years.
In addition, in March of last year, the company signed an exclusive domestic sales contract with Galderma Korea for ‘L-Cranel Alpha Liquid (ingredient name: alphatradiol)’, an external treatment for hair loss, and began full-fledged domestic sales and marketing activities. L-Cranel Alpha solution is a treatment for androgenetic alopecia that can be used by both men and women and minimizes hair loss by triply inhibiting the production of dihydrotestosterone, the cause of hair loss. It is simple to use as it is applied to the scalp using an applicator, and it is non-sticky after application, providing an excellent feeling of use.
Expanding lineup from hair loss treatments to hair care cosmetics
JW Shinyak signed an exclusive domestic sales contract with Pierre Fabre for ‘Ducray Neoptide Expert’ last year and began official sales in January. Ducray Neoptide Expert is a hair care cosmetics released through high-level research and development and human application testing. As a result, JW Shinyak has expanded its hair care lineup by entering the hair care cosmetics market following the finasteride and dutasteride series of hair loss treatments.
JW Shinyak is responsible for the domestic distribution and sales of Ducray Neoptide Expert based on its sales and marketing competitiveness accumulated in the clinic market, and Pierre Fabre is introducing Ducray Neoptide Expert product for the first time in Asia through this contract.
Pierre Fabre is a leading French pharmaceutical company that first introduced the concept of ‘dermocosmetics’, which combines skin health and beauty. It owns about 10 brands, including Europe’s number one dermocosmetics brand Avene, Ducray, Aderma, Rene Furterer, and Klorane. Ducray’s total brand sales are around 200 million euros (about 280 billion won), of which the hair care product line accounts for about 25% (about 70 billion won).
Professional hair care cosmetics developed through clinical trials
Dermocosmetic is a compound word of ‘Dermatology’, which means skin science, and ‘Cosmetic’, and refers to cosmetics exclusive to pharmacies or cosmetics made by skin experts. Since research and development and clinical trials are carried out at a similar level to pharmaceutical products, consumer trust is quite high in that they can be used with confidence.
Ducray Neoptide Expert is a hair care cosmetics released through high-level research and development and human application testing. Recently, JW Shinyak began a global phase 4 clinical trial for Ducray Neoptide Expert. It will be conducted for six months from September 2024 to March 2025 to follow up on the effects of using the product and improve safety. It is scheduled to be held simultaneously in 15 countries around the world, including Europe, Asia, the Middle East, South America, and Africa, and in Korea, JW Shinyak will be in charge.
Ducray Neoptide Expert can be used in combination with patients who need hair care and hair transplant patients, as well as patients using existing hair loss treatments such as minoxidil or finasteride. It is also easy to use as it is a cosmetic product that is lightly sprayed on the scalp. Ducray Neoptide Expert, sold by JW Shinyak, can be found at hair loss treatment hospitals and clinics, including dermatology clinics, across the country.
Reporter Park Yun-jeong [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-09-30 16:25:33